Pricing
DPC +
COMPLETE
ROOTED
$150 / Month
Direct Primary Care
Quarterly Lab Review
20% off supplements
Weight loss
Hormone Optimization
Health Coaching $50 / Visit
Urgent Care $60 / Visit
Concierge Services $100 / Visit
Added Member $125/ Month
Added Youth $100 / Month
MOST POPULAR
DPC PLAN
ROOTED
COMPLETE
ROOTED
$175 / Month
All DPC+ +
Functional Medicine
Meal Guides
4 Health Coaching Visits
Added Member Discounts
Free Challenges
MOST POPULAR
FUNCTIONAL MED PLAN
COMPLETE
COMPLETE
COMPLETE
$200 / Month
All Foundational +
3 Monthly provider visits
4 Urgent Care Visits
6 Health Coaching Visits
*ALL Plans: 3+ month Commitment
*All Plans: Exclude medication and lab cost
Health Coaching and Urgent care visits based on annual cycle
Semaglutide
What it is:
Semaglutide is a medication belonging to the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). It is used in the treatment of type 2 diabetes and for weight management.
What it does:
For diabetes treatment, semaglutide works by mimicking the effects of a hormone called glucagon-like peptide-1 (GLP-1), which stimulates insulin release, lowers glucagon secretion, and slows down the rate at which food is absorbed in the stomach. This helps regulate blood sugar levels.
For weight management, higher doses of semaglutide have been approved as an adjunct to diet and exercise for chronic weight management in adults with obesity or overweight and at least one weight-related condition. The exact mechanism for weight loss is not fully understood, but it is believed to involve reduced hunger and increased feelings of fullness.
Results:
Results vary, but It typically takes about two weeks for semaglutide to start working in the body. Some people begin to see results within the first eight weeks, but most begin to see results within 12 weeks.
Studies have shown that study participants taking a weekly dose of semaglutide had an average reduction in body weight of 5-10 percent (2), and in longer studies, some had a weight loss of up to 20% (1).
Common Side Effects:
- Gastrointestinal Issues: Nausea, vomiting, diarrhea, constipation, and abdominal pain are among the common gastrointestinal side effects. Likely this is related to slowed gastric emptying. Although rare, more severe risks include bowel obstruction, and pancreatitis.
- Hypoglycemia: As semaglutide may lower blood sugar levels, there is a risk of hypoglycemia (low blood sugar), particularly if used in combination with other medications that lower blood sugar.
- Injection Site Reactions: Given as an injectable, semaglutide may cause reactions at the injection site, such as redness or itching.
Contraindications:
- Hypersensitivity: Semaglutide should not be used in individuals with a known hypersensitivity or allergy to semaglutide or any of its components.
- Personal or Family History of Medullary Thyroid Carcinoma (MTC): Given the potential risk of MTC, semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): Semaglutide is contraindicated in individuals with MEN 2, as these individuals may have an increased risk of MTC.
*Tumors associated with rodents, particularly in mice, during preclinical studies.
It's important to note that the information provided here is a general overview, and specific details can vary. Results and side effects continue to be studied. Statistics reported may become out of date. Always consult a healthcare professional or refer to the official prescribing information for the most accurate and up-to-date details about semaglutide, its uses, and potential side effects.
References:
(1) Garvey, W.T., Batterham, R.L., Bhatta, M. et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28, 2083–2091 (2022). https://doi.org/10.1038/s41591-022-02026-4
(2)Ghusn W, De la Rosa A, Sacoto D, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022;5(9):e2231982. doi:10.1001/jamanetworkopen.2022.31982
Tirzepatide
What it is:
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It combines the benefits of two hormones to improve blood sugar control and promote weight loss.
Uses:
- Type 2 Diabetes Management: Tirzepatide has demonstrated effectiveness in improving glycemic control in individuals with type 2 diabetes.
- Weight Management: Clinical trials have shown significant weight loss in participants treated with Tirzepatide, making it a promising option for those struggling with obesity.
Results:
Results vary. Studies report, an average, a 20% mean weight reduction in patients classified as overweight or obese without diabetes after taking the medication for 36 weeks. However, when abruptly stopped, patients regained 14% (2.)
Common Side Effects:
While Tirzepatide can be well-tolerated, some individuals may experience side effects. Common ones include:
- Gastrointestinal Issues: Nausea, vomiting, diarrhea, and abdominal discomfort are common side effects. These often subside as the body adjusts to the medication.
- Hypoglycemia: As Tirzepatide lowers blood sugar levels, there is a risk of hypoglycemia. Monitoring blood sugar levels is crucial, especially if used in combination with other antidiabetic medications.
- Injection Site Reactions: Given as a subcutaneous injection, some individuals may experience reactions at the injection site, such as redness or itching.
Contraindications:
- Hypersensitivity: Tirzepatide should not be used in individuals with a known hypersensitivity or allergy to tirzepatide or any of its components.
- Personal or Family History of Medullary Thyroid Carcinoma (MTC): Given the potential risk of MTC, tirzepatide may be contraindicated in individuals with a personal or family history of medullary thyroid carcinoma.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): Tirzepatide may be contraindicated in individuals with MEN 2 due to the increased risk of MTC associated with this condition.
- Severe Gastrointestinal Disease: The presence of severe gastrointestinal disease may be a consideration, as tirzepatide can cause gastrointestinal side effects. It should be used with caution in individuals with a history of gastrointestinal disorders.
- Pancreatitis: Tirzepatide, like other GLP-1 receptor agonists, has been associated with an increased risk of pancreatitis. Caution is advised in individuals with a history of pancreatitis.
It's important to note that the information provided here is a general overview, and specific details can vary. Results and side effects continue to be studied. Statistics reported may become out of date.
Always consult with a healthcare provider for personalized advice and to understand the latest information regarding contraindications and precautions associated with tirzepatide or any medication.
References:
(1) Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. Published online December 11, 2023. doi:10.1001/jama.2023.24945
(2) Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022 Jul 5;27(13):4315. doi: 10.3390/molecules27134315. PMID: 35807558; PMCID: PMC9268041.